Y-90 internal liver radiation followed by tremelimumab and durvalumab for liver cancer with portal vein thrombosis

A Multicenter Open-label, Prospective Study to Evaluate the Efficacy and Safety of SIRT Using Yttrium-90 Glass Microspheres Followed by Durvalumab and Tremelimumab for Treatment of Hepatocellular Carcinoma With Portal Vein Thrombosis

This will test whether Y-90 selective internal radiation (SIRT) followed by tremelimumab and durvalumab helps people with non-resectable hepatocellular carcinoma that involves the portal vein.

Quick facts

• Phase: Phase 2
• Study type: Interventional
• Enrollment: 80 (estimated)
• Ages: 18 Years and up
• Sex: All
• Sponsor: Center Eugene Marquis (Academic / other)
• Drugs / interventions: durvalumab, tremelimumab, immunotherapy, radiation, prednisone, nivolumab
• Locations: 6 sites (Grenoble and 5 other locations)
• Trial ID: NCT07122089 on ClinicalTrials.gov

What this trial studies

The trial plans to enroll about 80 patients and treat roughly 72 after screening and SIRT eligibility checks. Each participant receives Y-90 glass microsphere SIRT, then begins a single injection of tremelimumab followed by durvalumab started 1–3 weeks later, with durvalumab continued every 4 weeks until progression or unacceptable toxicity. Eligible patients must have HCC with segmental/sectorial/lobar portal vein thrombosis, no extrahepatic spread, preserved liver function (Child‑Pugh A, ALBI 1–2), ECOG 0–1, measurable disease and at least 30% untreated hepatic reserve. Patients are followed for outcomes up to a maximum of 18 months after starting immunotherapy.

Who should consider this trial

Good fit: Adults with non-resectable hepatocellular carcinoma involving segmental, sectorial or lobar portal vein thrombosis, no extrahepatic spread, preserved liver function (Child‑Pugh A, ALBI 1–2), ECOG 0–1, measurable disease and at least 30% untreated hepatic reserve are the intended candidates.

Not a fit: Patients with main portal vein thrombosis, extrahepatic metastases, poor liver function (Child‑Pugh B/C), or ECOG >1 are excluded and unlikely to benefit from this regimen.

Why it matters

Potential benefit: If successful, this approach could extend survival or improve tumor control for HCC patients with portal vein thrombosis who have limited current options.

How similar studies have performed: Other immunotherapy regimens have shown positive results in advanced HCC and SIRT is an established option for PVT patients, but the specific sequence of Y-90 followed by tremelimumab plus durvalumab is relatively novel with limited prior data.

Eligibility criteria

Inclusion Criteria:

1. Age ≥ 18,
2. ECOG Performance Status 0-1,
3. Histologically proven HCC or noninvasive HCC diagnosis according to LiRADS criteria,
4. HCC with Portal vein involvement (PVT), segmental, sectorial or lobar, evaluated by diagnostic imaging (CT scan or MRI),
5. At least one measurable lesion≥ 10mm using mRECIST criteria evaluated by diagnostic imaging,
6. Tumor involvement \<50% of the liver,
7. Hepatic reserve after SIRT ≥ 30% (i.e. hepatic parenchyma not treated with SIRT) evaluated by diagnostic imaging
8. No cirrhosis or Compensated cirrhosis (Child Pugh A, ALBI score 1 or 2),
9. SIRT indication confirmed by a multidisciplinary team meeting (i.e. patient not a candidate for liver resection, thermal ablation, or transplantation at the time of study),
10. Registration with a social security scheme,
11. Written and informed consent of the patient.

Exclusion Criteria:

1. Patient with main PVT (partial or complete),
2. Extrahepatic metastases (patients with EHS), except hilum node \< 2 cm,
3. Previous episode of ascites and/or presence of ascites, even if only seen on imaging without clinical detection (except minimum blade only peri-hepatic),
4. Previous episode of hepatic encephalopathy and/or hepatic encephalopathy presence at study entry and/or episodes of encephalopathy (Grade ≥2) within 6 months prior to study inclusion,
5. Pulmonary insufficiency (defined by an arterial oxygen pressure (PaO2) of \<60 mmHg, or oxygen saturation (SaO2) of \<90% (Roussos \& Koutsoukou, 2003) or clinically evident chronic obstructive pulmonary disease (COPD),
6. Medical history of radiation pneumonitis or recent pneumonitis, regardless of causality,
7. Previous HCC therapies:

   1. Any prior systemic treatment for HCC;
   2. More than 2 prior TACE (or embolization), in the area to be treated;
   3. Liver resection or ablation \<6 months from end of previous treatment to TheraSphere administration;
   4. Liver ablation \<3 months from end of previous treatment to TheraSphere administration.
8. Prior exposure to immune mediated therapy for HCC or other disease, such as other anti-PD-1, anti-PDL-1, anti-PDL-2, anti-CTLA-4, antibodies, etc.
9. Previous liver radiation (external beam radiation therapy (EBRT) or peptide receptor radionuclide therapy (PRRT) or SIRT
10. Inadequate hematological, hepatic and renal functions:

    1. Hemoglobin \<8,5 g/dl;
    2. Granulocytes \<1500/mm3;
    3. Platelets \< 50 000 /mm3;
    4. Bilirubin level ≥35 umol/l;
    5. Albumin \<28g/L;
    6. Transaminases \> 5 UNL;
    7. Creatinine \> 1,5 UNL;
    8. INR\>2 (or TP \<60%) without anti-coagulation.
11. Any contraindication to angiography or selective visceral catheterization,
12. History of any organ allograft, including bone marrow allo and autograft,
13. History of active primary/acquired immunodeficiency, that makes patients unsuitable for additional immunotherapy in this study (per investigator),
14. Active or prior documented autoimmune or inflammatory disorders (including but not limited to inflammatory bowel disease \[e.g. ulcerative colitis or Crohn's disease\], systemic lupus erythematosus, Sarcoidosis syndrome, or Wegener syndrome \[granulomatosis with polyangiitis, Graves' disease, rheumatoid arthritis, hypophysitis, uveitis\]). The following are exceptions to this criterion:

    1. Patients with vitiligo or alopecia;
    2. Patients with hypothyroidism (e.g. following Hashimoto's syndrome) stable on hormone replacement therapy;
    3. Any chronic skin condition that does not require systemic therapy;
    4. Patients with celiac disease controlled by diet alone.
15. Current or prior use of immunosuppressive medication within 14 days before the first dose of durvalumab. The following are exceptions to this criterion: Intranasal, inhaled, topical steroids, or local steroid injections (e.g. intra-articular injection),
16. In the case of background systemic corticosteroid use, doses of prednisone or its equivalent \>10 mg/day,
17. Need for premedication of hypersensitivity reactions with Steroids (e.g. CT scan premedication),
18. History of gastrointestinal bleeding within 42 days prior to study inclusion, active GI bleeding and any bleeding diathesis or coagulopathy that is not correctable by usual therapy or hemostatic agents (e.g. closure device). Patients with known varices that have not bled or which have been clinically addressed can enter the study. No endoscopic exploration is required before study inclusion,
19. Presence of biliary stent or sphincterotomy within one year prior to study inclusion,
20. History of malignancy, other than HCC, within two years, except the condition is one of the following:

    1. Adequately treated carcinoma in situ of the cervix, early squamous cell carcinoma or basal cell carcinoma of the skin, localized prostate cancer, breast ductal carcinoma in situ, or low-grade endometrial carcinoma with no myometrial invasion;
    2. Localized prostate cancer under active surveillance;
    3. Other cancer when there is a negligible risk of recurrence or progression or death (5-year OS rate \> 90%).
21. Major surgical procedure (as defined by the Investigator) within 42 days prior to study inclusion,
22. A history of severe allergy or intolerance to contrast agents, narcotics, sedatives, or atropine that cannot be managed medically,
23. Known allergy or hypersensitivity to any of the study drugs or any of the study drug excipients that cannot be managed medically,
24. Active infection, including:

    1. Tuberculosis (clinical evaluation that includes clinical history, physical examination and radiographic findings, and tuberculosis testing in line with local practice),
    2. HBV\* and Hep D co-infection,
    3. Human immunodeficiency virus\*\* (HIV 1/2 antibodies) plus HCV or HBV\* co-infection.

       * Patients with active HBV infection or HCV infection must be managed according to local standard of care. Patients must show evidence of viral disease stabilization prior to inclusion.

         * Patients with Human Immunodeficiency Virus (HIV) infection are eligible, provided the HIV infection is well controlled with no current or previous AIDS-related complications and CD4+ T-cell (CD4+) counts ≥ 350 cells/µL
25. Receipt of live attenuated vaccine within 30 days prior to the first dose of durvalumab and/or tremelimumab. Note: patients, if enrolled, should not receive live vaccine whilst receiving durvalumab and/or tremelimumab and up to 30 days after the last dose of durvalumab and/or tremelimumab,
26. Participation in another clinical trial in the 4 weeks prior to enrollment, unless it is an observational study or a 4-week no-treatment follow-up phase of an interventional study,
27. Female patients who are pregnant (a negative serum pregnancy test is mandatory for inclusion) or breastfeeding and who do not want to stop breastfeeding. Male or female patients of reproductive potential who are not willing to employ any effective birth control method from screening and for at least 3 months post the last dose of study treatment (durvalumab ± tremelimumab and/or TheraSphere), whichever is later,
28. Unstable chronic disease or evidence of any disease or condition that would place the patient at undue risk and preclude safe use of TheraSphere, durvalumab and tremelimumab treatment as deemed by the site principal investigator,
29. Patients who are not able to follow the TheraSphere, durvalumab or tremelimumab treatment requirements,
30. Persons deprived of their liberty by a judicial or administrative decision, persons subject to psychiatric care under articles L. 3212-1 and L. 3213-1 who are not covered by the provisions of Article L. 1121-8 and persons admitted to a health or social establishment for purposes other than research, including:

    1. Persons receiving psychiatric treatment;
    2. Persons admitted to a health or social establishment for purposes other than research;
    3. Person of full age under curatorship;
    4. Adult subject to a mandate for future protection, a family authorization, or a guardianship measure.

Angiograhy and dosimetry exclusion criteria:

1. Cone Beam CT (CBCT) or Technetium-99m Macro Aggregated Albumin (99mTc-MAA) hepatic arterial perfusion scintigraphy shows any deposition to the gastrointestinal tract that may not be corrected by angiographic techniques,
2. 99mTc-MAA hepatic arterial perfusion scintigraphy shows poor tumor targeting and/or a poor portal vein thrombosis (PVT) targeting (99mTc-MAA uptake ≤ normal liver uptake),
3. The dosimetry endpoints cannot be reached (refer to the supplement A "TheraSphere Treatment Planning, Dosimetry Guidance document"),
4. Shunting of blood to the lungs that could result in delivery of \>30 Gy to the lungs in a single treatment, or \>50 Gy cumulative dose to the lungs in case of multiple TheraSphere treatments, as seen on 99mTc-MAA hepatic arterial perfusion scintigraphy.

Where this trial is running

Grenoble and 5 other locations

• CHU de Grenoble — Grenoble, France (Active_not_recruiting)
• CHU de Lille — Lille, France (Active_not_recruiting)
• La Timone — Marseille, France (Not_yet_recruiting)
• CHU de Montpellier — Montpellier, France (Active_not_recruiting)
• CHU de Nice — Nice, France (Active_not_recruiting)
• Centre Eugène Marquis — Rennes, France (Recruiting)

Study contacts

• Principal investigator: Etienne Garin, MD PHD — Centre de Lutte Contre Le cancer Eugène Marquis
• Study coordinator: Tassadit AMROUN-SEBILLE

Conditions Hepatocellular Carcinoma Non-resectable; Hepatocellular carcinoma; Immunotherapy; Selective internal radiation therapy